This is a working overview of Albumin conjugation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
=== Animal studies === Multiple animal studies have investigated the biological activity of D-ribose-L-cysteine in models of oxidative stress and metabolic injury. These studies have reported that D-ribose-L-cysteine supplementation increases intracellular and tissue glutathione levels, improves antioxidant enzyme activity, and reduces markers of oxidative damage in rodents. In several experimental models, D-ribose-L-cysteine demonstrated equal or greater glutathione-enhancing effects compared with N-acetylcysteine, though these findings are limited to preclinical settings.
=== Names === Flunitrazepam is marketed under many brand names in the countries where it is legal. It also has many street names, including "roofie" and "ruffie". It is also known as Circles, Forget Me Pill, La Rocha, Lunch Money Drug, Mexican Valium, Pingus, R2, and Roach 2.
A number of former Wildcats have gone on to pursue successful professional NBA careers (especially during the Lute Olson era), including Gilbert Arenas, Richard Jefferson, Mike Bibby, Jason Terry, Sean Elliott, Damon Stoudamire, Khalid Reeves, Luke Walton, Hassan Adams, Salim Stoudamire, Andre Iguodala, Channing Frye, Brian Williams (later known as Bison Dele), Sean Rooks, Jud Buechler, Michael Dickerson, Chase Budinger, Jordan Hill, Jerryd Bayless, Derrick Williams, Kadeem Allen, Aaron Gordon, Solomon Hill, Rondae Hollis-Jefferson, Stanley Johnson, T.J McConnell, Lauri Elias Markkanen, Kobi Simmons, Steve Kerr, Deandre Ayton, Rawle Alkins, and Allonzo Trier. Kenny Lofton, now best known as a former Major League Baseball star, was a four-year letter winner as a Wildcat basketball player (and was on the 1988 Final Four team), before one year on the Arizona baseball team. Another notable former Wildcat basketball player is Eugene Edgerson, who played on the 1997 and 2001 Final Four squads, and spent some of his professional careers as one of the Harlem Globetrotters as "Wildkat" Edgerson.
== Recovery == As operator of the warehouse property, Lineage Inc., is responsible for debris removal, including 85 million pounds of food debris, site cleanup, and public nuisance mitigation, including odor mitigation and pest control. On July 13 2026, after more than 40 complaints from locals, South Coast Air Quality Management District issued a formal citation to Lineage for failure to control foul odor. Several relief funds have been established to help recover from disruptions from the fire, including the CCF Impact Fund, activated by the California Community Foundation to provide immediate relief for residents affected by the fire. Donations will fund direct cash assistance through Angeleno Cards, food distribution, air purifiers, masks, water, and other emergency essentials delivered through vetted community partners; and the Boyle Heights Fire Relief Fund which provides emergency financial assistance to small businesses and street vendors impacted by the fire. The California Community Foundation has provided grants to more than 20 community organizations working with residents impacted by the Lineage fire.
Sources: en.wikipedia.org
CIS is a first episode of MS signs and symptoms, followed by a full or almost full recovery. To be classified as CIS, the attack must last at least a full day and be due to demyelination or inflammation of the central nervous system. Individuals with CIS can in some cases be diagnosed directly with MS, if they meet more strict criteria compared to people with a history of attacks. Radiologically isolated syndrome is diagnosed when an MRI for an unrelated issue shows MS-like lesions. Similarly, people can be diagnosed with MS if they meet more strict criteria. RRMS is characterized by unpredictable relapses followed by periods of weeks to years of relative quiet (remission). Deficits that occur during attacks may either resolve fully or leave some problems. In between attacks, there is often silent progression of the disease (progression independent of relapse activity). RRMS describes the initial course of 85% of individuals with MS. RRMS can sometimes develop into SPMS, as attack frequency declines and there is clear worsening between attacks. In practical terms, the diagnosis of SPMS is typically only made in people with a minimum amount of disability. Occasional relapses and minor remissions may appear. Less frequently, MS starts as PPMS, which is characterised by a progressive worsening in the absence of attacks, from disease onset. Symptoms may become slightly less severe temporarily.
Flow Chart of Metabolic Pathways at ExPASy IUBMB-Nicholson Metabolic Pathways Chart SuperCYP: Database for Drug-Cytochrome-Metabolism Archived 3 November 2011 at the Wayback Machine Metabolic pathways
Shooting the elephant to take its tusks: this method is of concern here. Taking tusks from an elephant which has died of natural causes. Taking tusks from an elephant which has had to be put down for another reason, for example, severe arthritis, or if its last molar teeth are worn out and can no longer chew its food. Among working elephants which use their tusks to carry logs, there is an optimal tusk length. In former times, tusks were often cut back to this length (and often the shortened tusks' ends were bound in copper). This periodically freed pieces of ivory for the carving trade.
Streptococcus agalactiae (also known as group B streptococcus or GBS) is a gram-positive coccus (round bacterium) with a tendency to form chains (as reflected by the genus name Streptococcus). It is a beta-hemolytic, catalase-negative, and facultative anaerobe. S. agalactiae is the most common human pathogen of streptococci belonging to group B of the Rebecca Lancefield classification of streptococci. GBS are surrounded by a bacterial capsule composed of polysaccharides (exopolysaccharide). The species is subclassified into ten serotypes (Ia, Ib, II–IX) depending on the immunologic reactivity of their polysaccharide capsule. The plural term group B streptococci (referring to the serotypes) and the singular term group B streptococcus (referring to the single species) are both commonly used synonymously with S. agalactiae even though S. halichoeri and S. pseudoporcinus are also group B Streptococcus. These species test positive as group B, but are not frequently carried by humans and only rarely cause disease.
== Mechanism of action == The toxin cleaves SNARE proteins, preventing the release of acetylcholine at the neuromuscular junction and producing flaccid paralysis. Botulinum toxin exerts its effect by cleaving key proteins required for nerve activation. First, the toxin binds specifically to presynaptic surface of neurons that use the neurotransmitter acetylcholine. Once bound to the nerve terminal, the neuron takes up the toxin into a vesicle by receptor-mediated endocytosis. As the vesicle moves farther into the cell, it acidifies, activating a portion of the toxin that triggers it to push across the vesicle membrane and into the cell cytoplasm. Botulinum neurotoxins recognize distinct classes of receptors simultaneously (gangliosides, synaptotagmin and SV2). Once inside the cytoplasm, the toxin cleaves SNARE proteins (proteins that mediate vesicle fusion, with their target membrane bound compartments) meaning that the acetylcholine vesicles cannot bind to the intracellular cell membrane, preventing the cell from releasing vesicles of neurotransmitter. This stops nerve signaling, leading to flaccid paralysis. The toxin itself is released from the bacterium as a single chain, then becomes activated when cleaved by its own proteases. The active form consists of a two-chain protein composed of a 100-kDa heavy chain polypeptide joined via disulfide bond to a 50-kDa light chain polypeptide.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.